Literature DB >> 28413657

A feasibility study of bevacizumab and vinorelbine in patients with previously treated advanced non-squamous non-small-cell lung cancer.

Kyohei Kaburaki1, Kazutoshi Isobe1, Hiroshi Kobayashi1, Takahiro Yoshizawa1, Yujiro Takai1, Sakae Homma1.   

Abstract

The aim of this prospective study was to evaluate the efficacy and feasibility of bevacizumab combined with vinorelbine therapy in patients with previously treated non-squamous non-small-cell lung cancer (nonSq-NSCLC). Patients who had received at least one prior chemotherapy course were eligible for this study. The patients were treated with vinorelbine (25 mg/kg on days 1 and 8) and bevacizumab (15 mg/kg on day 1), which was repeated every 3 weeks until the development of progressive disease or unacceptable toxicity. Between June, 2011 and January, 2013, 15 patients were enrolled. The response and disease control rates were 26.7 and 73.3%, respectively. The median progression-free survival was 2.1 months and the median overall survival was 34.1 months. Grade 3-4 phlebitis occurred in 3 patients. Therefore, the combination of vinorelbine and bevacizumab was found to be effective in patients with previously treated nonSq-NSCLC, but physicians must be aware of the risk of phlebitis associated with this regimen.

Entities:  

Keywords:  bevacizumab; phlebitis; vinorelbine

Year:  2017        PMID： 28413657      PMCID： PMC5374907          DOI： 10.3892/mco.2017.1187

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN： 2049-9450


  26 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial).

Authors:  M Yoshida; K Muro; A Tsuji; Y Hamamoto; T Yoshino; K Yoshida; K Shirao; Y Miyata; D Takahari; T Takahashi; A Ohtsu
Journal:  Eur J Cancer       Date:  2015-03-30       Impact factor: 9.162

3.  Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer.

Authors:  Tetsuya Kubota; Yoshio Okano; Mizu Sakai; Masato Takaoka; Tsukie Tsukuda; Kazuki Anabuki; Shigeo Kawase; Shintaro Miyamoto; Hiroshi Ohnishi; Nobuo Hatakeyama; Hisanori Machida; Tomoyuki Urata; Akira Yamamoto; Fumitaka Ogushi; Akihito Yokoyama
Journal:  Anticancer Res       Date:  2016-01       Impact factor: 2.480

4.  Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.

Authors:  C Kosmas; N Tsavaris; C Panopoulos; M Vadiaka; N Stavroyianni; T Kourelis; N Malamos; M Antonopoulos; H P Kalofonos
Journal:  Eur J Cancer       Date:  2001-05       Impact factor: 9.162

5.  Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.

Authors:  Cesare Gridelli; Francesco Perrone; Ciro Gallo; Silvio Cigolari; Antonio Rossi; Francovito Piantedosi; Santi Barbera; Francesco Ferraù; Elena Piazza; Francesco Rosetti; Maurizia Clerici; Oscar Bertetto; Sergio Federico Robbiati; Luciano Frontini; Cosimo Sacco; Federico Castiglione; Adolfo Favaretto; Silvia Novello; Maria Rita Migliorino; Giampietro Gasparini; Domenico Galetta; Rosario Vincenzo Iaffaioli; Vittorio Gebbia
Journal:  J Natl Cancer Inst       Date:  2003-03-05       Impact factor: 13.506

6.  Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.

Authors:  Y Ohe; Y Ohashi; K Kubota; T Tamura; K Nakagawa; S Negoro; Y Nishiwaki; N Saijo; Y Ariyoshi; M Fukuoka
Journal:  Ann Oncol       Date:  2006-11-01       Impact factor: 32.976

7.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Authors:  Takashi Seto; Terufumi Kato; Makoto Nishio; Koichi Goto; Shinji Atagi; Yukio Hosomi; Noboru Yamamoto; Toyoaki Hida; Makoto Maemondo; Kazuhiko Nakagawa; Seisuke Nagase; Isamu Okamoto; Takeharu Yamanaka; Kosei Tajima; Ryosuke Harada; Masahiro Fukuoka; Nobuyuki Yamamoto
Journal:  Lancet Oncol       Date:  2014-08-27       Impact factor: 41.316

8.  Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer.

Authors:  Steven F Powell; Amer Beitinjaneh; Mathewos Tessema; Robin L Bliss; Robert A Kratzke; Joseph Leach; Arkadiusz Z Dudek
Journal:  Clin Lung Cancer       Date:  2013-06-28       Impact factor: 4.785

9.  Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.

Authors:  Roy S Herbst; Vincent J O'Neill; Louis Fehrenbacher; Chandra P Belani; Philip D Bonomi; Lowell Hart; Ostap Melnyk; David Ramies; Ming Lin; Alan Sandler
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544

10.  Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.

Authors:  Paxton V Dickson; John B Hamner; Thomas L Sims; Charles H Fraga; Catherine Y C Ng; Surender Rajasekeran; Nikolaus L Hagedorn; M Beth McCarville; Clinton F Stewart; Andrew M Davidoff
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.